Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesEndocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline
Journal of Clinical Endocrinology and Metabolism, 06/22/09
Hembree WC et al. - Transsexual persons seeking to develop the physical characteristics of the desired gender require a safe and effective hormone regimen that will suppress endogenous hormone secretion determined by the person's genetic/biologic sex and maintain sex hormone levels within the normal range for the person's gender. The authors recommend treating transsexual adolescents (Tanner stage 2) with suppression of puberty with GnRH analogues until age 16 years, after which cross-sex hormones may be given. They suggest suppression of endogenous sex hormones, maintaining physiologic levels of gender-appropriate sex hormones and surveillance for known risks and complications in adult transsexual persons.
Wylie C. Hembree, 07/20/09
| As the chair of this guideline's writing task force, I must inform the reader that the version of the guideline posted on June 22 to MDLinx is in draft form. The Endocrine Society is currently finalizing this guideline and the final version will be published in the September issue of the Journal of Clinical Endocrinology & Metabolism. One of the changes that will be included in the September published version is the change to the dosage in Table 12. The correct dosage of Parenteral: estradiol in MTF transsexual persons is 5-20 mg im every 2 wk and the correct dosage for Spironolactone is 100-200 mg/d. Please continue to visit The Endocrine Society website at: http://www.endo-society.org/guidelines/index.cfm for information and updates regarding this guideline. Please also feel free to contact The Endocrine Society with questions or requests at govt-prof@endo-society.org. |
Today in Reproductive Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
The Effect of Metformin Treatment for 2 Years without Caloric Restriction on Endocrine and Metabolic Parameters in Women with Polycystic Ovary Syndrome
Experimental and Clinical Endocrinology & Diabetes, 12/10/09
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome
Diabetes Care, 11/30/09
Review of the safety, efficacy, costs and patient acceptability of recombinant follicle-stimulating hormone for injection in assisting ovulation induction in infertile women
International Journal of Women's Health, 11/30/09
Sponsor
Article Search
Sponsor